ZeroStack Corp. is an asset management and pharmaceutical distribution company that integrates artificial intelligence, digital assets, and global wholesale operations. The company operates at the intersection of decentralized AI infrastructure and traditional pharmaceutical markets, positioning itself as a hybrid player in emerging and established industries. ZeroStack’s strategy centers on accumulating and managing digital assets, particularly 0G Tokens, while maintaining a pharmaceutical distribution business through its German subsidiary, Phatebo GmbH.

The company generates revenue primarily through its pharmaceutical distribution segment, which supplies a range of prescription medications, including cancer therapies, ADHD treatments, multiple sclerosis drugs, and antidepressants. In its digital assets segment, ZeroStack does not yet derive direct revenue but aims to create long-term value through strategic holdings, staking activities, and AI-driven asset management. The company’s treasury strategy involves accumulating cryptocurrencies, such as 0G and Bitcoin, with plans to leverage these assets for future income generation or capital appreciation.

The company operates through the following segments:

• Digital Assets and AI: This segment focuses on building and managing a treasury of digital assets, with a long-term strategy centered on accumulating 0G Tokens. ZeroStack intends to hold these assets for capital appreciation and explore revenue-accretive opportunities, such as staking and AI-driven asset management. The segment also monitors regulatory developments to ensure compliance while pursuing growth in decentralized AI infrastructure.

• Commercial and Wholesale: This segment encompasses the distribution of pharmaceutical products, primarily through Phatebo GmbH, which operates in Germany. Phatebo imports and exports a wide range of medications, serving healthcare providers, pharmacies, and patients across Europe. The segment leverages Germany’s position as a leading pharmaceutical market to drive revenue and expand its product offerings.

ZeroStack Corp. occupies a unique position in both the digital assets and pharmaceutical industries. In the digital assets space, the company competes with larger treasury management firms, blockchain protocols, and AI-focused asset managers. Its competitive advantage lies in its early adoption of 0G Tokens and its focus on decentralized AI infrastructure, which aligns with growing demand for scalable, verifiable AI solutions. In the pharmaceutical distribution market, ZeroStack benefits from Phatebo’s established operations in Germany, a key hub for pharmaceutical sales in Europe. The company’s hybrid model allows it to diversify risk while capitalizing on high-growth opportunities in AI and blockchain.

The company’s customer base is divided between its two core segments. In pharmaceutical distribution, ZeroStack serves hospitals, pharmacies, and healthcare providers across Europe, with a strong presence in Germany. The digital assets segment does not yet have a direct customer base but targets institutional and retail investors interested in decentralized AI and blockchain technologies. Specific customer names are not disclosed in the filing.